TAŞ, F. Et Al. 2013. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. TUMOR BIOLOGY , vol.34, no.6 , 3529-3536.

TAŞ, F., KARABULUT, S., Bilgin, E., Sen, F., YILDIZ, İ., TAŞTEKİN, D., ... Ciftci, R.(2013). Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. TUMOR BIOLOGY , vol.34, no.6, 3529-3536.

TAŞ, Faruk Et Al. "Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma," TUMOR BIOLOGY , vol.34, no.6, 3529-3536, 2013

TAŞ, Faruk Et Al. "Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma." TUMOR BIOLOGY , vol.34, no.6, pp.3529-3536, 2013

TAŞ, F. Et Al. (2013) . "Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma." TUMOR BIOLOGY , vol.34, no.6, pp.3529-3536.

@article{article, author={Faruk TAŞ Et Al. }, title={Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma}, journal={TUMOR BIOLOGY}, year=2013, pages={3529-3536} }